Literature DB >> 15762888

Alpha-fodrin as a putative autoantigen in Graves' ophthalmopathy.

G J Kahaly1, H Bang, W Berg, M Dittmar.   

Abstract

Alpha-fodrin, an intracellular organ-specific cytoskeleton protein is a recently identified autoantigen associated with Sicca- and Sjogren's syndrome (SS). SS frequently affects patients with Graves' ophthalmopathy (GO). We have therefore cloned and expressed the human recombinant 120-kDa fodrin-fragment. A sequential purification procedure was applied to isolate the recombinant protein. Using sera from patients with SS, the antigenicity of the purified fodrin fragment was demonstrated by immunoblotting. Sera from 144 patients with GO and 1200 blood donors were screened for the presence of anti-alpha-fodrin IgA and IgG antibodies by a newly developed ELISA using the human alpha-fodrin fragment as an autoantigen. In contrast to controls (<1% IgA only, P < 0.001) and to subjects with various autoimmune diseases (P < 0.001), alpha-fodrin antibodies were detected in 22% of patients with GO (n = 32). IgA and IgG antibodies were present in 21 (15%) and 14 (10%) GO subjects, respectively. A total of 45 patients with GO (31%) had at least one fodrin- or SS-antibody. GO patients with SS showed SS- and high titres of alpha-fodrin-antibodies. In GO patients, fodrin antibodies correlated with TPO- (P < 0.05) and SS-A (P = 0.002) antibodies. Thus, for the first time, antibodies reactive with fodrin are reported in patients with GO.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15762888      PMCID: PMC1809346          DOI: 10.1111/j.1365-2249.2004.02750.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  24 in total

1.  Inflammatory cytokine regulation of Fas-mediated apoptosis in thyroid follicular cells.

Authors:  J D Bretz; P L Arscott; A Myc; J R Baker
Journal:  J Biol Chem       Date:  1999-09-03       Impact factor: 5.157

2.  Severe destructive autoimmune lesions with aging in murine Sjögren's syndrome through Fas-mediated apoptosis.

Authors:  N Ishimaru; T Yoneda; K Saegusa; K Yanagi; N Haneji; K Moriyama; I Saito; Y Hayashi
Journal:  Am J Pathol       Date:  2000-05       Impact factor: 4.307

Review 3.  Graves' disease.

Authors:  A P Weetman
Journal:  N Engl J Med       Date:  2000-10-26       Impact factor: 91.245

4.  Possible involvement of EBV-mediated alpha-fodrin cleavage for organ-specific autoantigen in Sjogren's syndrome.

Authors:  H Inoue; K Tsubota; M Ono; Y Kizu; F Mizuno; K Takada; K Yamada; K Yanagi; Y Hayashi; I Saito
Journal:  J Immunol       Date:  2001-05-01       Impact factor: 5.422

5.  Cleavage of the actin-capping protein alpha -adducin at Asp-Asp-Ser-Asp633-Ala by caspase-3 is preceded by its phosphorylation on serine 726 in cisplatin-induced apoptosis of renal epithelial cells.

Authors:  B van de Water; I B Tijdens; A Verbrugge; M Huigsloot; A A Dihal; J L Stevens; S Jaken; G J Mulder
Journal:  J Biol Chem       Date:  2000-08-18       Impact factor: 5.157

6.  Effect of tumor necrosis factor-alpha, interferon-gamma, and transforming growth factor-beta on adipogenesis and expression of thyrotropin receptor in human orbital preadipocyte fibroblasts.

Authors:  R W Valyasevi; S C Jyonouchi; C M Dutton; N Munsakul; R S Bahn
Journal:  J Clin Endocrinol Metab       Date:  2001-02       Impact factor: 5.958

7.  TRAIL death pathway expression and induction in thyroid follicular cells.

Authors:  J D Bretz; M Rymaszewski; P L Arscott; A Myc; K B Ain; N W Thompson; J R Baker
Journal:  J Biol Chem       Date:  1999-08-13       Impact factor: 5.157

8.  Identification of alpha-fodrin as a candidate autoantigen in primary Sjögren's syndrome.

Authors:  N Haneji; T Nakamura; K Takio; K Yanagi; H Higashiyama; I Saito; S Noji; H Sugino; Y Hayashi
Journal:  Science       Date:  1997-04-25       Impact factor: 47.728

9.  Leishmania major parasites express cyclophilin isoforms with an unusual interaction with calcineurin.

Authors:  C Rascher; A Pahl; A Pecht; K Brune; W Solbach; H Bang
Journal:  Biochem J       Date:  1998-09-15       Impact factor: 3.857

10.  Anti-120-kDa alpha-fodrin immune response with Th1-cytokine profile in the NOD mouse model of Sjögren's syndrome.

Authors:  K Yanagi; N Ishimaru; N Haneji; K Saegusa; I Saito; Y Hayashi
Journal:  Eur J Immunol       Date:  1998-10       Impact factor: 5.532

View more
  6 in total

1.  Autoantibody against aldehyde dehydrogenase 2 could be a biomarker to monitor progression of Graves' orbitopathy.

Authors:  Kai-Chun Cheng; Yu-Jen Wu; Kai-Hung Cheng; Kai-Yuan Cheng; Kuo-Jen Chen; Wen-Chuan Wu; Po-Yen Lee; Cheng-Hsien Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2018-02-03       Impact factor: 3.117

2.  Proteomic analysis of the differences in orbital protein expression in thyroid orbitopathy.

Authors:  Kai-Chun Cheng; Han-Hsiang Huang; Chun-Tzu Hung; Cheng-Chi Chen; Wen-Chuan Wu; Jau-Ling Suen; Kuo-Jen Chen; Yu-Jen Wu; Cheng-Hsien Chang
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2013-08-28       Impact factor: 3.117

Review 3.  Thyroid disease in Sjögren's syndrome.

Authors:  Luis J Jara; Carmen Navarro; María del Pilar Brito-Zerón; Mario García-Carrasco; Ricardo O Escárcega; Manuel Ramos-Casals
Journal:  Clin Rheumatol       Date:  2007-06-09       Impact factor: 2.980

4.  A systematic review of multimodal clinical biomarkers in the management of thyroid eye disease.

Authors:  Stephanie Hiu Ling Poon; Janice Jing-Chee Cheung; Kendrick Co Shih; Yau Kei Chan
Journal:  Rev Endocr Metab Disord       Date:  2022-01-23       Impact factor: 6.514

Review 5.  Update on thyroid-associated Ophthalmopathy with a special emphasis on the ocular surface.

Authors:  Priscila Novaes; Ana Beatriz Diniz Grisolia; Terry J Smith
Journal:  Clin Diabetes Endocrinol       Date:  2016-11-16

6.  Chemosensitivity of U251 Cells to the Co-treatment of D-Penicillamine and Copper: Possible Implications on Wilson Disease Patients.

Authors:  Meghri Katerji; Kassem Barada; Mustapha Jomaa; Firas Kobeissy; Ahmad-Kareem Makkawi; Wassim Abou-Kheir; Julnar Usta
Journal:  Front Mol Neurosci       Date:  2017-01-31       Impact factor: 5.639

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.